{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:27:39Z","timestamp":1775064459908,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00228-020-03069-7","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T10:03:02Z","timestamp":1610704982000},"page":"955-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0636-051X","authenticated-orcid":false,"given":"Amanda R.","family":"Buckallew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie B.","family":"Tellor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Mbachu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay R.","family":"Seltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia L.","family":"Armbruster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"3069_CR1","doi-asserted-by":"crossref","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jim\u00e9nez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee (2018) Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137(12):e67\u2013e492","DOI":"10.1161\/CIR.0000000000000558"},{"issue":"4","key":"3069_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","volume":"4","author":"A Ali","year":"2008","unstructured":"Ali A, Campbell R (2008) Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin 4(4):387\u2013399","journal-title":"Heart Fail Clin"},{"issue":"16","key":"3069_CR3","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride P, McMurray J, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines (2013) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147\u2013e239","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3069_CR4","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride P, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 136(6):e137\u2013e161","journal-title":"Circulation."},{"issue":"10","key":"3069_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341(10):709\u2013717","journal-title":"N Engl J Med"},{"key":"3069_CR6","unstructured":"National Kidney Foundation (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1\u2013150"},{"issue":"15","key":"3069_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay S, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"6","key":"3069_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543\u2013551","journal-title":"N Engl J Med"},{"issue":"11","key":"3069_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/jcm7110459","volume":"7","author":"C Yang","year":"2018","unstructured":"Yang C, Kor C, Hsieh Y (2018 Nov) Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease. J Clin Med 7(11):459","journal-title":"J Clin Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03069-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03069-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03069-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:16:13Z","timestamp":1623068173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03069-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3069"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03069-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"17 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Amanda Buckallew, Rachel Watson, William Miller, Gina Mbachu, Cameron Whitlock, Jay Seltzer, and Anastasia Armbruster do not have anything to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this manuscript. Katie Tellor was employed at St. Louis College of Pharmacy when the research was conducted and analyzed, and during the initial drafting of the manuscript. She is currently an employee and stockholder of Pfizer, Inc. and contributed to the final approval of the current version during her employment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}